The Supportive Effect of Acarbose to Orlistat in Weight Management-A Randomized, Double-Blind, Multiarm Phase 2 Trial.

ABSTRACT:

Objective

This study aimed to evaluate the added effect of acarbose to orlistat on relative weight loss in the novel antiobesity medication EMP16.

Methods

In this 6-month double-blind trial, 240 individuals with obesity or overweight and comorbidities were randomized equally into three groups: (1) EMP16 (120 mg modified release orlistat/40 mg modified release acarbose), (2) MR-O (120 mg modified release orlistat), and (3) Conv-O (120 mg conventional orlistat). The primary outcomes were relative and categorical weight loss after 6 months.

Results

Mean relative weight loss was -7.73% for the EMP16 group as compared to -5.78% for the MR-O group and -5.13% for the Conv-O group (p < 0.01). Proportion achieving ≥ 5% or ≥ 10% weight reduction was 61%/32% in EMP16 group, comp

SUBMITTER: Holmback U 

PROVIDER: S-EPMC12477108 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature